Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

Seoul National University

Status and phase

Completed

Phase 2

Conditions

Methicillin-Resistant Staphylococcus Aureus

Pneumonia, Staphylococcal

Treatments

Drug: Vancomycin

Study type

Interventional

Funder types

Other

Identifiers

NCT01925066

B-1206-156-004

Details and patient eligibility

About

The purpose of this study is to determine whether aerosolized vancomycin is effective in the treatment of methicillin-resistant staphylococcus aureus pneumonia under mechanical ventilation.

Enrollment

20 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Nosocomial or severe community-acquired pneumonia due to Methicillin-Resistant Staphylococcus aureus
Must be mechanically ventilated in intensive care unit

Exclusion criteria

Non-bacterial pneumonia, such as viral, fungal, tuberculosis infections
Underlying respiratory condition: bronchiectasis, post-tuberculosis, chronic obstructive pulmonary disease or asthma
Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or drainage
Already or previous treated with intravenous vancomycin (Not pneumonia)
Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin
Hypersensitivity of vancomycin or glycopeptide antibiotics
Positive culture of Enterococcus in respiratory specimen
Pregnant or Breast-feeding patient
Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3 months, transplantation recipients, AIDS patients
Another aerosolized antibiotics within 48 hours of study enrollment
Not adherent to mechanical ventilation protocol of this study
Not arterial line monitoring
Vancomycin minimum inhibitory concentration >= 2㎍/㎖ of cultured Staphylococcus aureus